Ascendis Pharma A/S, incorporated on September 21, 2006, is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark) and Ascendis Pharma Growth Disorders A/S (Denmark).
TransCon human Growth Hormone
The Company is developing TransCon hGH as a prodrug with once-weekly administration that releases unmodified growth hormone, maintaining the same mode of action as daily hGH therapies. The Company initiated a pivotal global Phase III study of TransCon hGH, the heiGHt Trial, in children with GHD. In addition, the Company is developing an auto-injector with Medicom Innovation Partner A/S for administration of TransCon hGH for the pediatric population.
TransCon PTH
The Company is developing TransCon PTH for hypoparathyroidism, an endocrine disorder of calcium and phosphate metabolism. TransCon PTH is designed as a once-daily formulation of PTH (1-34) to maintain a steady concentration of PTH in the bloodstream within the normal range.
TransCon C-Type Natriuretic Peptide
The Company is developing TransCon C-Type Natriuretic Peptide (TransCon CNP) for the treatment of achondroplasia, a form of dwarfism. TransCon CNP is designed as a once-weekly formulation of a CNP peptide. The Company is engaged in completing a preclinical primate study comparing weekly TransCon CNP to an approximately three times higher cumulative daily dose of a synthesized molecule with the same amino acid sequence as vosoritide.
TransCon Treprostinil
The Company is developing prodrug formulations of TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a disease characterized by elevated blood pressure in the pulmonary arteries. The Company is developing an inhaled formulation of TransCon Treprostinil for once-daily administration and a formulation designed as a once-daily subcutaneous injection.
TransCon Peptides
The Company is developing TransCon Peptides for the treatment of diabetes. The Company is researching and developing long-acting TransCon prodrugs.
TransCon Ranibizumab
TransCon Ranibizumab is a compound designed to support up to half-yearly injection of ranibizumab. It enables the predictable release of an active parent drug from its biodegradable carrier system.
The Company competes with Nektar Therapeutics, OPKO Health, Inc., ProLynx LLC, Serina Therapeutics, Inc., Bioton S.A., Critical Pharmaceuticals, Ltd., Dong-A Pharmaceutical, GeneScience Pharmaceuticals Co., Ltd., Genexine Inc., Hanmi Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Versartis, Inc., Shire plc, Chugai Pharmaceutical Co., Ltd., Extend Biosciences, Massachusetts General Hospital, Eli Lilly and Company, BioMarin Pharmaceuticals, Inc., Therachon, BioClin Therapeutics, Inc, Actelion Pharmaceuticals Ltd., GlaxoSmithKline LLC, Insmed Inc. and United Therapeutics Corporation.
Tuborg Boulevard 5
The company trades on NASDAQ exchange. The company headquarter is located in Denmark. The company was established in the 2006.| Ticker | ASND |
| Long Name | Ascendis Pharma A/S |
| Short Name | Ascendis Pharma AS |